Xenetic Biosciences and VolitionRx have entered into a research and development collaboration to develop neutrophil extracellular traps (NETs)-targeted, adoptive cell therapies for the treatment of cancer.

Caris Life Sciences and Xencor have entered into a multi-year strategic option and license agreement to research, develop and commercialize XmAb bispecific antibodies directed against novel targets for the treatment of patients with cancer.

A study led by researchers at the Institut Curie and INSERM has identified a means of overcoming CD8+ T-cell exhaustion and loss of cytotoxic activity in tumors.

Cellectis announced that the FDA has cleared its IND application to initiate a phase I/IIa clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (NHL).

Ipsen and Marengo Therapeutics have entered into a strategic partnership to advance two of Marengo's preclinical STAR (Selective T Cell Activation Repertoire) platform-generated candidates into the clinic.